- Home
- FGEN vs NRXP Comparison
FGEN vs NRXP Comparison
Compare FGEN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- NRXP
- Stock Information
- Founded
- FGEN 1993
- NRXP 2015
- Country
- FGEN United States
- NRXP United States
- Employees
- FGEN N/A
- NRXP N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- NRXP Health Care
- Exchange
- FGEN Nasdaq
- NRXP Nasdaq
- Market Cap
- FGEN 33.5M
- NRXP 32.6M
- IPO Year
- FGEN 2014
- NRXP N/A
- Fundamental
- Price
- FGEN $5.85
- NRXP $3.39
- Analyst Decision
- FGEN Strong Buy
- NRXP Strong Buy
- Analyst Count
- FGEN 1
- NRXP 4
- Target Price
- FGEN $250.00
- NRXP $28.50
- AVG Volume (30 Days)
- FGEN 60.4K
- NRXP 267.4K
- Earning Date
- FGEN 08-05-2025
- NRXP 08-13-2025
- Dividend Yield
- FGEN N/A
- NRXP N/A
- EPS Growth
- FGEN N/A
- NRXP N/A
- EPS
- FGEN N/A
- NRXP N/A
- Revenue
- FGEN $6,996,000.00
- NRXP N/A
- Revenue This Year
- FGEN N/A
- NRXP N/A
- Revenue Next Year
- FGEN N/A
- NRXP N/A
- P/E Ratio
- FGEN N/A
- NRXP N/A
- Revenue Growth
- FGEN N/A
- NRXP N/A
- 52 Week Low
- FGEN $4.50
- NRXP $1.10
- 52 Week High
- FGEN $38.25
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- FGEN 43.29
- NRXP 60.08
- Support Level
- FGEN $5.37
- NRXP $2.90
- Resistance Level
- FGEN $5.73
- NRXP $3.53
- Average True Range (ATR)
- FGEN 0.41
- NRXP 0.19
- MACD
- FGEN 0.07
- NRXP -0.03
- Stochastic Oscillator
- FGEN 77.78
- NRXP 84.13
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.